Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Alnylam Pharma and Sanofi Enter into Agreement 14
Regeneron Pharma Enters into Agreement with Alnylam Pharma 15
Invitae Enters into Agreement with Alnylam Pharma 16
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 17
BioXcel Enters into Agreement with Alnylam Pharma 18
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 19
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 21
Licensing Agreements 22
Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 22
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 26
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 27
Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 28
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 29
Equity Offering 30
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 30
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 32
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 34
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 36
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 37
Alnylam Pharma Completes Private Placement Of Shares For US$185 Million 39
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 41
Acquisition 43
Alnylam Pharma Acquires Sirna Therapeutics From Merck 43
Alnylam Pharmaceuticals Inc – Key Competitors 44
Alnylam Pharmaceuticals Inc – Key Employees 45
Alnylam Pharmaceuticals Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Joint Venture 47
Recent Developments 48
Strategy And Business Planning 48
Jan 07, 2018: Alnylam Announces 2018 Corporate Goals 48
Financial Announcements 50
Nov 07, 2018: Alnylam Pharmaceuticals reports third quarter 2018 financial results and highlights recent period activity 50
Aug 02, 2018: Alnylam Pharmaceuticals reports second quarter 2018 financial results and highlights recent period activity 53
May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 57
Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 60
Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 63
May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 65
Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 67
Corporate Communications 70
Oct 10, 2018: Alnylam appoints Dr. Margaret Hamburg to Board of Directors 70
Jun 20, 2018: Alnylam Pharmaceuticals Announces Senior Management Changes 71
May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 72
Jun 19, 2017: Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term 73
May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 74
Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 76
Legal and Regulatory 77
Oct 03, 2018: Kessler Topaz Meltzer & Check: securities fraud class action filed Against Alnylam Pharmaceuticals 77
Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 78
Apr 20, 2018: Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation 79
Nov 03, 2017: Silence Therapeutics: Update on litigation matters 80
Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 81
Government and Public Interest 82
Oct 29, 2018: Hochschulmedizin Zurich and Alnylam host Innovative Medicine lecture on the discovery and clinical applications of RNA interference (RNAi) 82
Oct 24, 2018: Alnylam announces Advocacy for Impact Grants to inspire unique solutions that address unmet needs affecting the rare disease community 83
Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 84
Product News 86
11/13/2017: European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis 86
11/03/2017: Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 87
10/03/2018: Kaskela Law LLC Announces Investor Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 89
10/02/2018: Alnylam launches ONPATTRO (patisiran), the first-ever RNAi therapeutic, in Germany 90
09/24/2018: Alnylam Pharmaceuticals receives Priority Review in Canada for Patisiran, an investigational RNAi Therapeutic for the treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy 91
08/30/2018: Alnylam receives approval of ONPATTRO (patisiran) in Europe 92
08/20/2018: Veristat congratulates Alnylam on the FDA approval of ONPATTRO (patisiran) 94
08/14/2018: Onpattro is the first FDA-approved treatment for polyneuropathy 95
08/10/2018: Alnylam announces alignment on value-based agreements with leading health insurers and launches comprehensive patient support services for ONPATTRO (patisiran) 96
08/10/2018: Alnylam announces first-ever FDA approval of an RNAi therapeutic, ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults 98
08/03/2018: Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Patisiran 100
07/27/2018: Alnylam receives positive CHMP opinion for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy 101
06/08/2018: Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) 103
03/12/2018: Alnylam Receives Breakthrough Therapy Designation from FDA for Lumasiran 105
Product Approvals 106
Aug 07, 2018: Silence Therapeutics litigation: patisiran EU marketing authorisation imminent 106
Mar 26, 2018: Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 107
Feb 01, 2018: Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 108
Jan 25, 2018: Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 109
Dec 18, 2017: Sanofi and Alnylam Submit Marketing Authorization Application to the EMA for Patisiran for the Treatment of Hereditary ATTR Amyloidosis 110
Dec 12, 2017: Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 111
Dec 11, 2017: Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis 112
Nov 16, 2017: Alnylam Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Patisiran for the Treatment of Hereditary ATTR Amyloidosis 113
Clinical Trials 114
Oct 08, 2018: Alnylam reports new positive Phase l/ll results from lumasiran trial 114
Sep 14, 2018: Alnylam announces publication in circulation of exploratory cardiac endpoint data from APOLLO phase 3 study of Patisiran 115
Jul 23, 2018: Alnylam presents new analyses of clinical results from APOLLO phase 3 study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting 117
Jul 04, 2018: Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine 119
Jun 15, 2018: Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology 121
May 08, 2018: Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery of RNAi Therapeutics 123
May 03, 2018: Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 124
Apr 24, 2018: Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting 125
Mar 28, 2018: Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis 127
Mar 14, 2018: Alnylam to Present Clinical Trial Data on Amyloidosis Drug Candidate ALN-TTRsc02 at the 16th International Symposium on Amyloidosis 129
Nov 20, 2017: U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy 130
Nov 02, 2017: Sanofi and Alnylam Present Positive Complete Results from APOLLO Phase 3 study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy 132
Oct 20, 2017: Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors 135
Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS) 136
Sep 20, 2017: Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program 137
Sep 20, 2017: Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy 138
Apr 26, 2017: Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis 140
Appendix 142
Methodology 142
About GlobalData 142
Contact Us 142
Disclaimer 142
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Alnylam Pharma and Sanofi Enter into Agreement 14
Regeneron Pharma Enters into Agreement with Alnylam Pharma 15
Invitae Enters into Agreement with Alnylam Pharma 16
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 17
BioXcel Enters into Agreement with Alnylam Pharma 18
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 19
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 21
Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 22
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 25
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 26
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 27
Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 28
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 29
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 30
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 32
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 34
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 36
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 37
Alnylam Pharma Completes Private Placement Of Shares For US$185 Million 39
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 41
Alnylam Pharma Acquires Sirna Therapeutics From Merck 43
Alnylam Pharmaceuticals Inc, Key Competitors 44
Alnylam Pharmaceuticals Inc, Key Employees 45
Alnylam Pharmaceuticals Inc, Subsidiaries 46
Alnylam Pharmaceuticals Inc, Joint Venture 47
List of Figures
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
